Pro12Ala PPAR γ2 gene polymorphism in PCOS women: the role of compounds regulating satiety

References

• Asunción M, Calvo RM, San Millán JL, Sancho J, Avila S, Escobar-Morreale HF. A prospective study of the prevalence of the polycystic ovary syndrome in unselected Caucasian women from Spain. J Clin Endocrinol Metab 2000;85:2434–2438.
   PubMed Web of Science ®Google Scholar
• Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil and Steril 2004;81:19–25.
   Web of Science ®Google Scholar
• Kennedy A, Gettys TW, Watson P, Wallace P, Ganaway E, Pan Q, Garvey WT. The metabolic significance of leptin in humans: Gender-based differences in relationship to adiposity, insulin sensitivity, and energy expenditure. J Clin Endocrinol Metab 1997;82:1293–1300.
   PubMed Web of Science ®Google Scholar
• Sepilian VP, Crochet JR, Nagamani M. Serum soluble leptin receptor levels and free leptin index in women with polycystic ovary syndrome: Relationship to insulin resistance and androgens. Fertil Steril 2006;85:1441–1447.
   PubMed Web of Science ®Google Scholar
• Bray GA, Atkinson RL. New weight guidelines for Americans. Am J Clin Nutr 1992;55:481–483.
   PubMedGoogle Scholar
• Katz A, Nambi SS, Mather K, Baron AD, Follmann DA, Sullivan G, Quon MJ. Quantitative insulin sensitivity check index: A simple, accurate method for assessing insulin sensitivity in humans. J Clin Endocrinol Metab 2000;85:2402–2410.
   PubMed Web of Science ®Google Scholar
• Ahrén B, Holst JJ, Efendic S. Antidiabetogenic action of cholecystokinin-8 in type 2 diabetes. J Clin Endocrinol Metab 2000;85:1043–1048.
   PubMed Web of Science ®Google Scholar
• Schwartz MW, Baskin DG, Bukowski TR, Kuijper JL, Foster D, Lasser G, Prunkard DE, et al. Specificity of leptin action on elevated blood glucose levels and hypothalamic neuropeptide Y gene expression in ob/ob mice. Diabetes 1996;45:531–535.
   PubMed Web of Science ®Google Scholar
• Milewicz A, Bidzińska B, Mikulski E, Demissie M, Tworowska U. Influence of obesity and menopausal status on serum leptin, cholecystokinin, galanin and neuropeptide Y levels. Gynecol Endocrinol 2000;13:1–8.
   Google Scholar
• Baranowska B, Chmielowska M, Radzikowska M, Borowiec M, Roguski K, Wasilewska-Dziubinska E. Effects of neuropeptide Y (NPY), galanin and vasoactive intestinal peptide (VIP) on pituitary hormone release and on ovarian steroidogenesis. Neuro Endocrinol Lett 1999;20:385–389.
   PubMedGoogle Scholar
• Brzechffa PR, Jakimiuk AJ, Agarwal SK, Weitsman SR, Buyalos RP, Magoffin DA. Serum immunoreactive leptin concentrations in women with polycystic ovary syndrome. J Clin Endocrinol Metab 1996;81:4166–4169.
   PubMed Web of Science ®Google Scholar
• Zukauskaite S, Seibokaite A, Lasas L, Lasiene D, Urbonaite B, Kiesylyte J. Serum hormone levels and anthropometric characteristics in girls with hyperandrogenism. Medicina (Kaunas) 2005;41:305–312.
   PubMedGoogle Scholar
• Baranowska B, Radzikowska M, Wasilewska-Dziubinska E, Kaplinski A, Roguski K, Plonowski A. Neuropeptide Y, leptin, galanin and insulin in women with polycystic ovary syndrome. Gynecol Endocrinol 1999;13:344–351.
   PubMed Web of Science ®Google Scholar
• Mantzoros CS, Dunaif A, Flier JS. Leptin concentrations in the polycystic ovary syndrome. J Clin Endocrinol Metab 1997;82:1687–1691.
   PubMedGoogle Scholar
• Rouru J, Anttila L, Koskinen P, Penttilä TA, Irjala K, Huupponen R, Koulu M. Serum leptin concentrations in women with polycystic ovary syndrome. J Clin Endocrinol Metab 1997;82:1697–1700.
   PubMed Web of Science ®Google Scholar
• Carmina E, Orio F, Palomba S, Cascella T, Longo RA, Colao AM, Lombardi G, Lobo RA. Evidence for altered adipocyte function in polycystic ovary syndrome. Eur J Endocrinol 2005;152:389–394.
   PubMed Web of Science ®Google Scholar
• Bray GA. Food intake, sympathetic activity, and adrenal steroids. Brain Res Bull 1993;32:537–541.
   PubMed Web of Science ®Google Scholar
• Kalra SP, Kalra PS. Neuropeptide Y: A physiological orexigen modulated by the feedback action of ghrelin and leptin. Endocrine 2003;22:49–56.
   PubMedGoogle Scholar
• Leibowitz SF, Akabayashi A, Alexander JT, Wang J. Gonadal steroids and hypothalamic galanin and neuropeptide Y: Role in eating behavior and body weight control in female rats. Endocrinology 1998;139:1771–1780.
   PubMed Web of Science ®Google Scholar
• Egido EM, Hernández R, Leprince J, Chartrel N, Vaudry H, Marco J, Silvestre RA. 26RFa, a novel orexigenic neuropeptide, inhibits insulin secretion in the rat pancreas. Peptides 2007;28:725–730.
   PubMedGoogle Scholar
• Karlsson S, Sundler F, Ahrén B. CCK receptor subtype in insulin-producing cells: A combined functional and in situ hybridization study in rat islets and a rat insulinoma cell line. Regul Pept 1998;78:95–103.
   PubMedGoogle Scholar
• Reidelberger RD. Cholecystokinin and control of food intake. J Nutr 1994;124:1327S–1333S.
   Google Scholar
• Degen L, Matzinger D, Drewe J, Beglinger C. The effect of cholecystokinin in controlling appetite and food intake in humans. Peptides 2001;22:1265–1269.
   PubMed Web of Science ®Google Scholar
• Bastard JP, Hainque B, Dusserre E, Bruckert E, Robin D, Vallier P, Perche S, et al. Peroxisome proliferator activated receptor-γ, leptin and tumor necrosis factor-α mRNA expression during very low calorie diet in subcutaneous adipose tissue in obese women. Diabetes Metab Res Rev 1999;15:92–98.
   PubMed Web of Science ®Google Scholar
• Vamecq J, Latruffe N. Peroxisome proliferator-activated receptors (PPARs) and their implications in diseases. Curr Opin Endocrinol Diabetol 2000;7:8–18.
   Google Scholar
• González Sánchez JL, Serrano Ríos M, Fernández Perez C, Laakso M, Martínez Larrad MT. Effect of the Pro12Ala polymorphism of the peroxisome proliferator-activated receptor γ-2 gene on adiposity, insulin sensitivity and lipid profile in the Spanish population. Eur J Endocrinol 2002;147:495–501.
   PubMed Web of Science ®Google Scholar
• Simón I, Vendrell J, Gutiérrez C, Fernández-Real JM, Vendrell I, Gallart L, Fontova R, Richart C. Pro12Ala substitution in the peroxisome proliferator-activated receptor-γ is associated with increased leptin levels in women with type-2 diabetes mellitus. Horm Res 2002;58:143–149.
   PubMedGoogle Scholar
• Meirhaeghe A, Cottel D, Amouyel P, Dallongeville J. Association between peroxisome proliferator-activated receptor γ haplotypes and the metabolic syndrome in French men and women. Diabetes 2005;54:3043–3048.
   PubMedGoogle Scholar
• Ben Ali S, Ben Yahia F, Sediri Y, Kallel A, Ftouhi B, Feki M, Elasmi M, et al. Gender-specific effect of Pro12Ala polymorphism in peroxisome proliferator-activated receptor γ-2 gene on obesity risk and leptin levels in a Tunisian population. Clin Biochem 2009;42:1642–1647.
   PubMed Web of Science ®Google Scholar
• Hahn S, Fingerhut A, Khomtsiv U, Khomtsiv L, Tan S, Quadbeck B, Herrmann BL, et al. The peroxisome proliferator activated receptor γ Pro12Ala polymorphism is associated with a lower hirsutism score and increased insulin sensitivity in women with polycystic ovary syndrome. Clin Endocrinol (Oxf) 2005;62:573–579.
   PubMed Web of Science ®Google Scholar
• Yilmaz M, Ergün MA, Karakoç A, Yurtçu E, Cakir N, Arslan M. Pro12Ala polymorphism of the peroxisome proliferator-activated receptor-γ gene in women with polycystic ovary syndrome. Gynecol Endocrinol 2006;22:336–342.
   PubMed Web of Science ®Google Scholar
• San-Millán JL, Escobar-Morreale HF. The role of genetic variation in peroxisome proliferator-activated receptors in the polycystic ovary syndrome (PCOS): An original case-control study followed by systematic review and meta-analysis of existing evidence. Clin Endocrinol (Oxf) 2010;72:383–392.
   PubMed Web of Science ®Google Scholar